Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) (VIKTORIA-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05501886 |
|
Recruitment Status :
Recruiting
First Posted : August 16, 2022
Last Update Posted : August 1, 2023
|
Sponsor:
Celcuity, Inc.
Information provided by (Responsible Party):
Celcuity, Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
This is a Phase 3, open-label, randomized, clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with locally advanced or metastatic HR+/HER2- breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Breast Cancer | Drug: Gedatolisib Drug: Palbociclib Drug: Fulvestrant Drug: Alpelisib | Phase 3 |
This is a Phase 3, open-label, randomized clinical trial evaluating the efficacy and safety of gedatolisib plus fulvestrant with or without palbociclib for the treatment of patients with advanced (inoperable) or metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) breast cancer following progression on or after CDK4/6 and aromatase inhibitor therapy. Gedatolisib is an intravenously administered pan-PI3K/mTOR inhibitor. Palbociclib is a CDK4/6 inhibitor. Fulvestrant is a selective estrogen receptor degrader (SERD). Subjects will be assessed for PIK3CA status and then randomized to treatment arms according to their confirmed PIK3CA mutation status.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 701 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy |
| Actual Study Start Date : | September 30, 2022 |
| Estimated Primary Completion Date : | September 30, 2024 |
| Estimated Study Completion Date : | September 30, 2026 |
Resource links provided by the National Library of Medicine
MedlinePlus Genetics related topics:
Breast cancer
MedlinePlus related topics:
Breast Cancer
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Arm A - Patients Lacking PIK3CA Mutations (WT)
Gedatolisib + Palbociclib + Fulvestrant
|
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
Drug: Palbociclib Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
Other Names:
Drug: Fulvestrant Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex |
|
Experimental: Arm B - Patients Lacking PIK3CA Mutations (WT)
Gedatolisib + Fulvestrant
|
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
Drug: Fulvestrant Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex |
|
Active Comparator: Arm C - Patients Lacking PIK3CA Mutations (WT)
Fulvestrant
|
Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex |
|
Experimental: Arm D - Patients with PIK3CA Mutation (MT)
Gedatolisib + Palbociclib + Fulvestrant
|
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
Drug: Palbociclib Palbociclib 125 mg PO given daily for 3 weeks (21 days), followed by 1 week off
Other Names:
Drug: Fulvestrant Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex |
|
Active Comparator: Arm E - Patients with PIK3CA Mutation (MT)
Alpelisib + Fulvestrant
|
Drug: Fulvestrant
Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex Drug: Alpelisib Alpelisib 300 mg PO (2 × 150 mg tablets) given daily for 4 weeks (28 days)
Other Names:
|
|
Experimental: Arm F - Patients with PIK3CA Mutation (MT)
Gedatolisib + Fulvestrant
|
Drug: Gedatolisib
Gedatolisib 180 mg IV given weekly for 3 weeks (Days 1, 8, 15) followed by 1 week off
Other Names:
Drug: Fulvestrant Fulvestrant 500 mg IM (2 × 5 mL injections) given every 2 weeks during Cycle 1 (Days 1 and 15), then every 4 weeks beginning with Cycle 2 Day 1
Other Name: Faslodex |
Primary Outcome Measures :
- Progression Free Survival (PFS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Approximately 48 months ]PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)
Secondary Outcome Measures :
- Overall Survival (OS) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From date of randomization to the date of death due to any cause, up to approximately 48 months ]OS is defined as the length of time from randomization until the date of death from any cause method, where PFS is defined as the time from randomization to death or the first documented progression, whichever occurs first, confirmed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria, as determined based on blinded independent central review (BICR)
- Overall Response Rate (ORR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]Percentage of subjects who achieved an objective response according to RECIST v1.1 criteria (complete response [CR] or partial response [PR]) as assessed by BICR)
- Duration of Response (DOR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]Time from the assessment of initial response (PR or better) to death or first documented disease progression as assessed by BICR, whichever occurs first
- Time to Response (TTR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]Time form randomization to the first assessment of PR or better as assessed by BICR, whichever comes first
- Clinical Benefit Rate (CBR) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: Up to approximately 48 months ]Percentage of subjects with CR, PR, or stable disease (SD) >24 weeks as assessed by BICR
- Quality of Life (QOL)Functional Assessment of Cancer Therapy - Breast Trial Outcome Index (FACT-B TOI) Questions in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]The FACT-B TOI is an abbreviated (24-item) version of the full FACT-B which focuses only on the patient's Physical Well-being (PWB), Functional Well-being (FWB), and Breast Cancer Subscale (BCS) components using a 5-level scale, (Not at all, A little bit, Some-what, Quite a bit, Very much).
- Quality of Life (QOL) NCCN-FACT Breast Symptom Index -16 (NFBSI-16) in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]NCCN-FACT is derived from the FACT-B and only 4 additional items will be administered to enable optional scoring of the NFBSI subscales and total score using a 5-level scale (Not at all, A little bit, Some-what, Quite a bit, Very much).
- Patient-Reported Outcomes in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]Patient-Reported Outcomes Measurement Information System (PROMIS®) Short Form v2.0 - Physical Function 8c using a 5-level scale (Without any difficulty, With a little difficulty, With some difficulty, With much difficulty, Unable to do)
- EuroQol 5 in Patients with PIK3CA WT and PIK3CA MT Breast Cancer [ Time Frame: From baseline to 30 Day Safety Follow-up ]EuroQol 5 Dimension 5 Level (EQ-5D-5L) - This is a 5 question, self-administered visual analog scale (VAS) where patients use 0 (worst health) to 100 (best health) to indicate how they view their health.
- Adverse Events [ Time Frame: Up to approximately 48 months ]Safety and tolerability will be evaluated by review of type, incidence, severity (as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] v5.0), seriousness, and relationship to study medications of adverse events (AEs) and any laboratory abnormalities
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Histologically or cytologically confirmed diagnosis of metastatic or locally advanced breast cancer Adult females, pre- and/or post-menopausal, and adult males. Pre-menopausal (and peri-menopausal) women can be enrolled if amenable to treatment with an LHRH agonist. Patients are to have commenced concomitant treatment with LHRH agonist prior to or on Cycle 1, Day 1 and must be willing to continue on it for the duration of the study.
- Negative pregnancy test for women of childbearing potential. Female subjects of childbearing potential must use an effective and/or acceptable contraceptive method from screening until 1 year after the last dose of study treatment
- Confirmed diagnosis of estrogen receptor positive and/or progesterone receptor positive, as per American Society of Clinical Oncology/College of American Pathologists (ASCO-CAP) guidelines (2020), based on most recent tumor biopsy utilizing an assay consistent with local standards
- Documented HER2 immunohistochemistry (IHC) negative as per ASCO-CAP 2018 guidance
- Adequate archival or fresh tumor tissue for the analysis of PIK3CA mutational status
- Subject must have documentation of radiological disease progression on or after the last prior treatment and also have radiologically evaluable disease (measurable and/or non-measurable) according to RECIST v1.1, per local assessment. Subjects with bone only disease must have lytic or mixed lytic/blastic lesions that can be accurately assessed; bone only blastic lesions with no soft tissue component is not allowed.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Life expectancy of at least 3 months
- Progressed during or after CDK4/6 inhibitor combination treatment with non-steroidal aromatase inhibitor (AI)
- Adequate bone marrow, hepatic, renal and coagulation function
Exclusion Criteria:
- History of malignancies other than adequately treated non-melanoma skin cancer, curatively treated in situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for ≥3 years
- Prior treatment with a phosphoinositide 3-kinase (PI3K) inhibitor, a protein kinase B (Akt) inhibitor, or a mechanistic target of rapamycin (mTOR) inhibitor
- Prior treatment with chemotherapy and antibody drug conjugates for advanced disease is not permitted (prior adjuvant or neoadjuvant chemotherapy is permitted)
- More than 2 lines of prior endocrine therapy treatment
- Bone only disease that is only blastic with no soft tissue component
- Subjects with type 1 diabetes or uncontrolled type 2 diabetes
-
Known and untreated, or active, brain or leptomeningeal metastases
a. Subjects with previously treated central nervous system (CNS) metastases may be enrolled in the study if they meet the following criteria: do not require supportive therapy with steroids; do not have seizures and do not exhibit uncontrolled neurological symptoms; stable disease confirmed by radiographic assessment within at least 4 weeks prior to enrollment
- Patients with advanced, symptomatic, visceral spread that are at risk of life-threatening complication in the short-term
-
History of clinically significant cardiovascular abnormalities such as: Congestive heart failure (New York Heart Association (NYHA) classification ≥ II within 6 months of study entry
- Myocardial infarction within 12 months of study entry
- History of any uncontrolled (or untreated) clinically significant cardiac arrhythmias, (e.g., ventricular tachycardia), complete left bundle branch block, high grade AV block (e.g., bifascicular block, Mobitz type II and third degree AV block), supraventricular, nodal arrhythmias, or conduction abnormality in the previous 12 months
- Uncontrolled hypertension defined by systolic blood pressure (SBP) ≥160 mmHg and/or diastolic blood pressure (DBP) ≥100 mmHg, with or without antihypertensive medication (initiation or adjustment of antihypertensive medication[s] is allowed prior to screening)
-
Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following:
- i. Risk factors for Torsades de Pointes (TdP) including uncorrected hypokalemia or hypomagnesemia, or history of clinically significant/symptomatic bradycardia
- ii. On screening, inability to determine the corrected QT interval using Fridericia's formula (QTcF) on the ECG (i.e., unreadable or not interpretable) or QTcF >480 msec (determined by mean of triplicate ECGs at screening)
- Known hypersensitivity to the study drugs or their components
- Pregnant or breast-feeding women
-
Concurrent participation in another interventional clinical trial
- Subjects must agree not to participate in another clinical trial (other than observational) at any time during participation in VIKTORIA-1.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05501886
Contacts
| Contact: Nadene Zack, MS | 844-310-3900 | VIKTORIA-1_TRIAL@CELCUITY.COM |
Locations
Show 218 study locations
Sponsors and Collaborators
Celcuity, Inc.
Investigators
| Study Director: | Nadene Zack | Celcuity, Inc. |
| Responsible Party: | Celcuity, Inc. |
| ClinicalTrials.gov Identifier: | NCT05501886 |
| Other Study ID Numbers: |
CELC-G-301 2021-005235-24 ( EudraCT Number ) |
| First Posted: | August 16, 2022 Key Record Dates |
| Last Update Posted: | August 1, 2023 |
| Last Verified: | July 2023 |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Celcuity, Inc.:
|
Breast Cancer, Advanced or Metastatic gedatolisib HR Positive ER Positive |
HER2 Negative PIK3CA MT PI3K |
Additional relevant MeSH terms:
|
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Fulvestrant Palbociclib Gedatolisib Antineoplastic Agents, Hormonal |
Antineoplastic Agents Estrogen Receptor Antagonists Estrogen Antagonists Hormone Antagonists Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |